Address
NCI Cancer Hospital
PT 13717, Jalan BBN 2/1
71800 Nilai,
Negeri Sembilan
Darul Khusus
Malaysia
Contact
Tel: +606-850 0999
Fax:
+606-850 0733
Visiting hours:
Mon - Sun : 9am- 9pm
Outpatient hours:
Mon - Sun : 24 hours
View location map
|
|
|
| |
 |
- A Randomized, Open label, parallel Group, International, Multicentre, Phase III Study of Oral ZD 1839 (IRESSA) Versus Intravenous Docetaxel (Taxotere) in Patients with Locally advanced or Metastatic Recurrent Non Small Cell Lung Cancer who have Previously Received Platinum Based Chemotherapy
September 2005. Principal Investigator : R Kananathan
Sponsor: Astra Zeneca
- A Phase III Trial of Novel Epothilone BMS –247550 Plus Capecitabine Versus Capecitabine Alone in patients with Advance Breast Cancer Previously Treated with or Resistance to an Antracycline and who are Taxane Resistance.
January 2005. Principal Investigator: Dr G Selvaratnam
Sponsor: Bristol-Myers Squibb
- A Phase III Randomised, Stratified, Parallel-Group, Multi Centre, Comparative Study of ZD 1839 (IRESSA) 250mg and 500mg versus Metotrexate for previously treated patients with squamous cell carcinoma of the head and neck.
June 2004. Principal Investigator: Dr Kananathan
Sponsor: Astra Zeneca
- Multicentre, open label, extension study of treatment with gefitinib (IRESSA) for patients completing other gefitinib clinical studies who benefited from gefitinib treatment.
October 2004. Prinicipal Investigator: Dr R Kananathan.
Sponsor: Astra Zeneca
- A double blind, placebo controlled, parallel group, multicentre, randomized, phase III survival study comparing ZD 1839 (IRESSA TM) (250mg tablet) plus best supportive care versus placebo plus best supportive care in patients with advanced NSCLC who have received one or two prior chemotherapy regimens and are refractory or intolerant to their most recent regimen.
August 2003. Principal Investigator Dr R Kananathan
Sponsor: Astra Zeneca
- PLUS 1 Patient Attitude and Lung Cancer Study in Advance Non Small Cell Lung Cancer.
November 2002. Principal Investigator Dr G Selvaratnam
Sponsor: Eli Lilly
- A comparative study of pharmacokinetic profile and pharmacodynamic effects of rHuGM-GSF (Leucomax) and GMX rHuGM-GSF (Neustin) in patients diagnosed with breast cancer undergoing chemotherapy. October 2002. Principal Investigator Dr G Selvaratnam
Sponsor: GeneMedix
- Ro 50-8231 Protocol BO 16411: A randomised, double blind, placebo controlled, multicentre, phase III study of Tarceva (erlotinib) plus chemotherapy (cisplatin and gemcitabine) versus chemotherapy alone in patients with advanced (stage IIIB and IV) non small cell lung cancer (NSCLC) who have not received prior chemotherapy.
October 2001. Principal Investigator Dr G Selvaratnam
Sponsor: Roche
- An open prospective study of imaging by Iodine-131 labelled chimaeric antibody, derived from super-high affinity sheep monoclonal antibodies (SMAs) of carcinoembryonic antigen (CEA), in post-surgical patients diagnosed with metastatic colorectal carcinoma.
May 2000. Principal Investigator Dr G Selvaratnam
Sponsor: KS Biomedix Holdings PLC - UK
|
|
|
|
|
